Agenus to Provide Second Quarter 2026 Financial Report and Development Update
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026.
Agenus plans to host a webcast later in August to discuss its corporate priorities, including the acceleration of the botensilimab and balstilimab (BOT+BAL) immunotherapy combination in the neoadjuvant colon cancer setting through the Phase 3 ROBBIN trial, upcoming clinical and data milestones, and ongoing efforts to support patient access to BOT+BAL. Additional details, including the webcast agenda and access information, will be provided prior to the event.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels.
